News · CTS Corporation (CTS) · Technology

CTS rises after quarterly beat and stronger outlook as Millar deal closes

Session of October 27, 2026 · Published October 28, 2026 · 3 min read

What happened

CTS rose 9.8% on October 27, 2026, after reporting third-quarter results that beat estimates and raising its outlook for full-year 2026 sales and adjusted earnings because of stronger sales, higher margins and the completion of the Millar acquisition. The company posted third-quarter 2026 earnings per share of $0.77 against $0.65 expected and recorded quarterly earnings of $0.77 per share versus $0.60 a year earlier. GlobeNewsWire reported the results and management commentary that cited higher revenue across diversified end markets, favorable product mix and operational execution.

Closing price over the last 30 trading sessions. On October 27, 2026, CTS closed at $59.22, up 9.8% on the day and 4.1% higher than 30 sessions earlier.

How big was the move

The stock opened 11.2% above the previous close and finished the session with trading volume at 1.6 times its 20-day average, showing a clear surge in investor activity. CTS rose 7.0% over the last five sessions while the S&P 500 rose 0.1% over five sessions, and the Technology sector median on the day rose 1.5%, making the move 8.3 percentage points better than the sector median. The session’s move measured 4.7 times a typical daily move for this stock and the stock has a beta of 1.44, meaning the stock tends to move more than the market.

Each bar is one day's price change; the outlined bar is October 27, 2026. A typical daily move over the past year was 2.2%, so the latest move equals 4.5 times that. Moves outside the dashed lines (about 4.3%) are unusual.

The technical picture

The stock traded above its short- and medium-term averages: 3.8% above its 20-day moving average, 3.2% above its 50-day moving average and 3.6% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend. The Relative Strength Index (14 days) stood at 58, in a neutral range between 30 and 70, while the stock remained 14.9% below the 52-week high.

Closing price over the past year. CTS ends the period 13.3% below its 52-week high, above its 50-day average ($57.39) and above its 200-day average ($57.14).

Over one month the stock fell 0.2% and over three months it fell 3.8%, but over one year it rose 40.5% and is 26.8 percentage points ahead of the S&P 500. Volatility was 33% annualized over 60 days, higher than 54% of its own readings over five years.

Fundamentals and valuation

For the four quarters through September 30, 2026, CTS reported revenue of $571.2 million, which grew 7.4% from a year earlier, and diluted earnings per share of $2.53, which rose 29.1% from a year earlier. Gross margin expanded to 40.3% from 38.1% a year earlier and operating margin improved to 16.8% from 15.3% a year earlier, reflecting management’s comments on product mix and execution. Free-cash-flow margin was 19.0% and return on invested capital was 9.8%. The balance sheet showed net cash of $55.1 million and share count over one year decreased by 2.4%.

Quarterly revenue by period end. The latest quarter brought $150M, 4.4% more than the same quarter a year earlier.

Valuation placed the stock at 23.4 times trailing earnings and 22.3 times expected earnings, with a free-cash-flow yield of 7.1%. Its price to trailing earnings was higher than 53% of its own readings over the past five years, with a five-year median of 23.4 times earnings. PromtFinance scores ranked Value 82 (Strong) and Quality 79 (Positive), while Growth scored 32 (Weak) and Revisions 34 (Weak), suggesting the market values current profitability more than near-term growth expectations.

Earnings and analyst expectations

The company’s last report was October 27, 2026: earnings per share of $0.77 against $0.65 expected, 17.9% above estimates. That result marked four consecutive quarters beating estimates, with an average surprise over the last four reports of 15.4% above estimates. Typical two-day reactions after recent reports saw the stock rise 1.4%, making the current session’s move larger than usual.

Diluted earnings per share by quarter. The latest quarter shows $0.61, against $0.46 in the same quarter a year earlier.

Analysts place a consensus price target of $73.50, which is 24.1% above the closing price, based on the views of four analysts with a consensus rating of Hold; 25% of those analysts rate the stock Buy or Strong Buy. The next report is scheduled for February 9, 2027. Management said the Millar acquisition expands its medical and industrial technology offerings and that the combination of upward guidance and the acquisition helped drive investor interest and higher trading volume.

What to watch

February 9, 2027: next scheduled earnings report.
Management’s updated full-year 2026 sales and adjusted earnings outlook following the October 27, 2026, report.
Integration and performance of the Millar acquisition and any disclosed contribution to revenue and margins.
Quarterly revenue trends and product-mix commentary, given the reported sales growth across diversified end markets.
Any changes to analyst estimates or consensus rating after the raised outlook.

Full CTS analysis: scores, chart and financials →